Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma

Immune checkpoint inhibitors (ICIs) have made important breakthrough in anti-tumor therapy, however, no single biomarker can accurately predict their efficacy. Studies have found that tumor microenvironment is a key factor for determining the response to ICI therapy. Cytokine receptor 3 (C-X-C Motif...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Wenqin, Lin, Anqi, Sun, Le, Wei, Ting, Ying, Haoxuan, Zhang, Jian, Luo, Peng, Zhu, Weiliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107140/
https://www.ncbi.nlm.nih.gov/pubmed/35562800
http://dx.doi.org/10.1186/s12935-022-02604-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107140/
https://www.ncbi.nlm.nih.gov/pubmed/35562800
http://dx.doi.org/10.1186/s12935-022-02604-z

Ejemplares similares